NL repository
menu
검색
Library
Browse
Communities & Collections
By Date
Authors
Titles
Subject
My Repository
My Account
Receive email updates
Edit Profile
DSpace at EWHA
의과대학
의학과
Journal papers
View : 240 Download: 0
Meibomian Gland Dysfunction Associated with Bortezomib in a Multiple Myeloma Patient
Title
Meibomian Gland Dysfunction Associated with Bortezomib in a Multiple Myeloma Patient
Authors
Yoon D.E.
;
Jun R.M.
;
Han K.E.
Ewha Authors
전루민
;
한경은
SCOPUS Author ID
전루민
; 한경은
Issue Date
2022
Journal Title
Journal of Korean Ophthalmological Society
ISSN
0378-6471
Citation
Journal of Korean Ophthalmological Society vol. 63, no. 4, pp. 389 - 395
Keywords
Bortezomib
;
Dry eye syndrome
;
Meibomian gland dysfunction
;
Multiple myeloma
Publisher
Korean Ophthalmological Society (KOS)
Indexed
SCOPUS; KCI
Document Type
Article
Abstract
Purpose: This study reports a case of meibomian gland dysfunction associated with bortezomib, which is a treatment of choice for multiple myeloma. Case summary: A 59-year-old female patient presented to our hospital with a complaint of dryness that had worsened for 2 months and eye discharges that were difficult to remove even after washing her face. The patient had been diagnosed with multiple myeloma 5 months prior and had undergone four cycles of bortezomib therapy. Slit-lamp microscopy revealed a number of pouting of the meibomian gland (MG) orifices in both eyes. Meibography revealed that more than one-third and less than two- thirds of the total MG area of both upper lids were lost and more than two-thirds of the total MG area of both lower lids were lost. No clinically significant improvements were noted at 8 months despite thorough eyelid hygiene therapy, including warm compresses, topical antibiotics, steroids, and artificial tears. However, when the patient revisited our clinic 2 months after completing bortezomib treatment, the subjective symptoms had improved and all of the pouting of MG orifices had disappeared. There was no significant difference in the MG dropout area for either eye compared with the observations from a previous visit during bortezomib treatment. Conclusions: Clinicians should be aware that MG dysfunction may occur or worsen in patients receiving bortezomib treatment and should consider this when establishing a treatment plan for meibomian dysfunction or when educating patients. J Korean Ophthalmol Soc 2022;63(4):389-395. © 2022 The Korean Ophthalmological Society.
DOI
10.3341/jkos.2022.63.4.389
Appears in Collections:
의과대학
>
의학과
>
Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML
Show full item record
Find@EWHA
트윗하기
BROWSE
Communities & Collections
By Date
Authors
Titles
Subject